Empyema, subdural
Ceftriaxone

Ceftriaxone

High
N/A

Spectrum Of Activity

General Information

Empiric therapy of:

  • Bacterial meningitis
  • Nosocomial gram negative infections (except Pseudomonas)
  • Spontaneous bacterial peritonitis
  • Hospitalized community or nursing home-acquired pneumonia in combination with a macrolide

Monitor CBC, hepatic and renal functions, previous hypersensitivity to other beta-lactam antibiotics, and signs of antibiotic-associated diarrhea and other superinfections.

Common

  • Diarrhea
  • Eosinophilia
  • Thrombocytosis
  • Injection site induration

Serious

  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Toxic epidermal necrolysis
  • Clostridium difficile colitis
  • Injury of lung
  • Renal failure
  • Hypersensitivity reaction
  • Hemolytic anemia
  • Kernicterus (newborn)

Contraindications:

  • Ringer's solution
  • Lactated Ringer's solution
  • Calcium-containing IV solutions

Major drug-drug interactions:

  • Cholera vaccine, live

Antimicrobial class: 3rd Generation Parenteral Cephalosporin

Pregnancy category: B

Average serum half life: 8 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Precautions:

  • Do not concurrently administer calcium-containing IV solutions in same IV line, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site; may be administered sequentially in patients other than neonates with thorough flushing of lines with compatible fluid between administrations.
  • Increased risk of drug toxicity in renal failure.
  • Use caution in patients with impaired vitamin K synthesis or low vitamin K stores due to risk of rare prothrombin time alteration.
  • Discontinue if hemolytic anemia occurs.
  • Use caution in patients with history of allergy.